ESR1 and breast cancer: In the report by Lalaoui et al., the subject matter of this commentary, the authors test the activity of potent dimeric SMs, exemplified by birinapant, against a panel of TN-BC and ER-positive BC patient-derived xenograft cell lines and established cell lines for viability and tumor growth6.